This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.
Jessica Guider, MS, MPH, MBA | |
630-364-3275 | |
[email protected] |
Eleanor Lisbon, MD, MPH | |
650-781-1765 | |
[email protected] |
18 Years - 55 Years
Phase 1
Interventional
All
Drug
Healthy males and females ≥ 18 to ≤ 55 years of age
Body mass index ≥ 18.0 to ≤ 30.0 kg/m2
Body weight ≥ 50 kg at screening and Day -1
– Positive pregnancy test or currently breastfeeding.